Martin Black, MD
Pulmonary Disease · Concord, NHNPI 1598938482
Payments from drug & device makers
What this record shows
This record is dominated by education: $4,000 of the $6,138 with a category attached, or 65.2%. Intuitive Surgical accounts for 97.1% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $4,412, more than ten times the $32 reported in 2019.
Across 20 payments — averaging $306.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Inari Medical, Inc.$46
- Regeneron Healthcare Solutions, Inc.$42
- Boehringer Ingelheim$32
- Insmed, Inc.$25
- GSK$18
- plus $15 from 1 others
What the payments were for
- Travel & lodging$1,82330%
- Food & beverage$3155%
- Education$4,00065%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $5,961 |
| Inari Medical, Inc. | 2 | $46 |
| Regeneron Healthcare Solutions, Inc. | 1 | $42 |
| Boehringer Ingelheim | 1 | $32 |
| Insmed, Inc. | 1 | $25 |
| GSK | 1 | $18 |
| AstraZeneca | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,767
How this compares
$6,138 in reported general payments places this provider in the 85th percentile of 78 pulmonary disease providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 270 | $240,268 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 160 | $137,159 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 68 | $53,943 |
| Spiriva RespimatTiotropium Bromide | 54 | $41,703 |
| Breo ElliptaFluticasone/Vilanterol | 67 | $38,211 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 68 | $36,401 |
| SymbicortBudesonide/Formoterol Fumarate | 105 | $28,009 |
| EliquisApixaban | 31 | $22,474 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $17,546 |
| Incruse ElliptaUmeclidinium Bromide | 30 | $16,463 |
| XareltoRivaroxaban | 11 | $15,165 |
| DuleraMometasone/Formoterol | 24 | $13,554 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $10,947 |
| Arnuity ElliptaFluticasone Furoate | 33 | $8,844 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 55 | $7,660 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $18 | $340,187468 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $15 | $172,238282 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $32 | $113,192136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 78 pulmonary disease providers in New Hampshire.
Other pulmonary disease in Concord
- David PiskorowskiConcord$3K
- Muneeb RahmanConcord$1K
- Soontharee CongreteConcord$639
- Arunima SharmaConcord$593
- Stephanie CullConcord$343
- Jennifer LacyConcord$268
- Alejandro SaranglaoConcord$65
- Lisa TilluckdharryConcord$40
- Donald MahlerLebanon$411K
- Bianca MonteiroDover$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.